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Prescription or pill-based methods for estimating adherence to antiretroviral therapy (ART), pharmacy
adherence measures (PAMs), are objective estimates calculated from routinely collected pharmacy data. We
conducted a literature review to evaluate PAMs, including their association with virological and other clinical
outcomes, their efficacy compared with other adherence measures, and factors to consider when selecting
a PAM to monitor adherence. PAMs were classified into 3 categories: medication possession ratio (MPR), pill
count (PC), and pill pick-up (PPU). Data exist to recommend PAMs over self-reported adherence. PAMs
consistently predicted patient outcomes, but additional studies are needed to determine the most predictive
PAM parameters. Current evidence suggests that shorter duration of adherence assessment (<6 months) and
use of PAMs to predict future outcomes may be less accurate. PAMs which incorporate the number of days for
which ART was prescribed without the counting of remnant pills, are reasonable minimum-resource methods
to assess adherence to ART.
Since the introduction of combination antiretroviral
therapy (ART) in the mid-1990s, human immunodefi-
ciency virus (HIV)–1 infected patients have experienced
decreasing levels of morbidity andmortality in both high-
income countries (HICs) and low- and middle-income
countries (LMICs) [1–3].
Successful HIV treatment largely depends on patient
adherence to ART. Suboptimal adherence predicts vi-
rological failure [4–7], the development of HIV drug
resistance [8–10], and death [11–13]. Standardized,
simple, and routine cost-effective monitoring of ad-
herence is necessary to identify patients at risk of poor
outcomes who would benefit from targeted adherence
support [14]. Two simple methods for assessing ad-
herence are patient self-report or prescription- or pill-
based adherence measures, referred to in this review as
‘‘pharmacy adherence measures’’ (PAMs). Unlike pa-
tient self-reported adherehence, which can be affected by
recall or social desirability bias, PAMs are objective and
may be calculated from information routinely available
in medical and pharmacy records [14].
The World Health Organization (WHO) recom-
mends the assessment of adherence to ART with every
patient contact [15]. Despite these recommendations,
there is no consensus regarding the optimal method to
estimate individual- and population-level adherence to
ART [15, 16]. This review summarizes currently avail-
able knowledge on PAMs, identifies their strengths and
limitations, proposes factors to consider when selecting
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a PAM to monitor adherence and predict treatment outcomes,
and identifies areas for future research.
DEFINITIONS AND SEARCH STRATEGY
PAMs are prescription- or pill-based adherence estimates cal-
culated using dates of prescription refills and/or pill counts
performed during routine clinic visits. Importantly, PAMs do
not include self-reported measures, PCs performed outside of
routine clinic visits (eg, unannounced PCs), monitoring of an-
tiretroviral drug levels or monitoring with electronic devices (eg,
electronic pill bottle [MEMS] caps). For purposes of clarity, we
define the period of time over which individual patient adher-
ence is estimated as ‘‘the duration of adherence assessment.’’ In
addition, we identify 3 broad categories of PAMs: MPR, PC, and
PPU. Definitions and formulae used to calculate these adherence
estimates are provided in Table 1.
We searched PubMed, the Cochrane Database of
Systematic Reviews, and the ISI Scientific Citation Index da-
tabases, using the terms ‘‘HIV’’ and ‘‘adherence’’ or ‘‘com-
pliance,’’ together with ‘‘pharmacy,’’ ‘‘prescription,’’ ‘‘pill
count,’’ ‘‘medication possession,’’ or ‘‘pick-up,’’ for articles
published from inception until April 2010. We also searched
reference lists of all included studies. All English-language
publications investigating associations between PAMs and the
following outcomes of interest were included: virological
failure or suppression (ie, viral load greater or less than a de-
fined threshold), change in viral load, immunological failure,
HIV drug resistance, or mortality. Studies in which the out-
come of interest occurred before the estimation of patient
adherence or in which estimates were calculated by combining
a PAM with an additional adherence measure were excluded.
If different adherence analyses were published using data from
a single cohort, we selected the publication that provided the
most information. Because of marked study heterogeneity,
meta-analyses were not performed.
ASSOCIATION BETWEEN PAMs AND PATIENT
OUTCOMES
In total, we identified 36 studies that met our inclusion criteria:
12 from LMICs (Table 2) [4, 13, 17–26] and 24 from HICs
(Table 3) [10, 11, 27–48]. All LMIC studies were from sub-
Saharan Africa. Eight LMIC studies used MPR [4, 13, 17, 19–
23], 3 used PC [18, 25, 26], and 1 used PPU [24]. HIC studies
included 18 studies from North America, 5 from Europe, and 1
from Australia. Sixteen studies from HICs estimated adherence
using MPR [10, 11, 27, 29–32, 34, 36–39, 41, 45, 47, 48], 5 used
PC [28, 33, 35, 40, 43], and 3 used PPU [42, 44, 46].
Association with Virological Outcomes
Twenty-seven (75%) of 36 studies reported virological out-
comes; 19 were from HICs [27–37, 39–45, 48], and 8 were from
LMICs [4, 17, 18, 22–26]. PAMs predicted virological failure in
14 (88%) of 16 studies, virological suppression in 8 (89%) of 9
studies, and viral load change in 3 (60%) of 5 studies. Studies
conducted in LMICs generally assessed ART-naive populations
receiving nonnucleoside reverse transcriptase inhibitor
(NNRTI)–containing regimens and demonstrated that PAMs
were predictive of either virological failure or virological sup-
pression. In contrast, all studies demonstrating no association
between PAMs and virological outcome were conducted in
HICs and assessed ART-experienced patients using smaller
sample sizes (<115 subjects; range, 40–115 subjects) [30, 31, 43,
Table 1. Pharmacy-Based Adherence Measure (PAM) Categories
PAM category Definition Formulae
Medication or drug
possession ratio
Measures the amount of time an
individual is in possession of >1 ARV
or prescriptions for the ARVs as a pro-
portion of the time between 2 ARV
pick-ups or prescriptions
Number of days ARV prescribed or
dispensed/number of days in the
interval
Pill count Measures the quantity of ARV pills an
individual has used between 2 ARV
pickups as a proportion of the number
of pills dispensed or as a proportion of
time between pick-ups
1. (Number of ARV pills dispensed –
number of ARV pills returned)/number
of ARV pills dispensed
2. (Number of days ARV pills dispensed –
number of days ARV pills returned)/
number of days in the interval
Pill pickup Measures whether an individual picks up
all or a majority of their prescribed
ARVs and expresses the adherence
estimate in a dichotomous fashion
(some measures require that ARVs be
picked up on or before the date the
previous ARV supply finishes).
1. Where ‘‘Adherent’’ 5 (ARV refills
picked up/ARV refills prescribed) .
predefined value
2. Where ‘‘Adherent’’ 5 (ARV refills
picked up prior to previous refill
finishing/ARV refills prescribed) .
predefined value
Note. ARV, antiretroviral
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Table 2. Reported Associations with Pharmacy-Based Adherence Measures (PAMs) in Low- and Middle-Income Countries
Study (year) Design
Type of
care Region
ART
naive
ART
regimen (%)a
PAM
category
PAM
definition
in study
PAM
monthsb
Sample
size, no.
of persons Key findingsc
Nachega et al
[13] (2006)
Retrospective
cohort
Private Sub-Saharan
Africa
(multiple
countries)
Yes NNRTI (82),
PI
MPR Months ART
claims submitted
(entire regimen)/
months from
start to death,
withdrawal
or censor
Variable;
median, 22
6288 1. PAM ,80% predicted
death and death 1 LTFU
(P , .01)
2. compared with PAM ad-
herence of 100%, de-
creasing PAM strata
increasingly predicted
death (P , .01), except
for PAM adherence of
80%–99%
MPR Months ART
claims submitted
(entire regimen)/
Months in the
interval
12 (0–12) 3267 PAM ,80% in first
12 months predicted
death (P , .01)
Weidle et al
[26] (2006)
Clinical trial Home based Uganda Yes NNRTI (100) PCf (Days 3TC delivered -
days 3TC returned)
/days in the interval
3 (3–6)
3 (9–12)
913
894
1. PAM ,95% predicted
VFd at 6 or 12 months
(P , .01)
2. self-report predicted VF
at 12 (P , .05) but not 6
months
PC (3TC Pills delivered
– 3TC pills
returned)/3TC pills
delivered
3 (3–6)
3 (9–12)
913
894
PAM ,95% predicted VFd
at 6 or 12 months (P ,
.05)
Nachega et al
[4] (2007)
Retrospective
cohort
Private Sub-Saharan
Africa
(multiple
countries)
Yes NNRTI (100) MPR Months ART claims
submitted (all
ARVs)/months
from start to
death/leaving/
censor
Variable
median, 26
2821 PAM strata .50%
increasingly predicted
sustained VL suppression
(P , .01), shorter time to
VL suppression (P, .05),
and increased time to vi-
ral rebound e (P , .05)
Bisson et al
[17] (2008)
Retrospective
cohort
Private Sub-Saharan
Africa
(multiple
countries)
Yes NNRTI (100) MPR Months ART claims
submitted (all
ARVs)/months
from start to
study endpoint
6 (0–6)
12 (0–12)
958
872
1. PAM ,90% predicted
VFc at 6 and 12 months
(P , .01)
2.it was better than changes
in the CD4 cell count at
predicting VFd at 6 and 12
months (P , .01)
Variable
median, 20
1101 1. PAM ,90% predicted
viral rebounde (P , .05)
2.not different than changes
in the CD4 cell count from
maximum on-treatment
value in predicting viral
rebounde
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3 (0–3)
3 (6–9)
958
872
PAM was no better than
changes in the CD4 cell
count over first 6 or 12
months in predicting VFc
at 6 or 12 months
Bisson et al
[18] (2008)
Case-control Public Botswana No NNRTI (100) PC Sum of (days ART
prescribed –
remnant days
ART) between
last and 3 prior
fills/days
between last and
3 prior fills
3 (varied) 302 1. Decreasing PAM rates
(90%-95%, 80%-90%,
and ,80%
2. (P, .05) and PAM,95%
(P , .01) in 3 months
prior to recruitment pre-
dicted VF,d compared
with PAM .95%
Goldman et al
[23] (2008)
Retrospective
cohort (all
clinical or IF)
Public Zambia Yes NNRTI (100) MPR 100% - [(days late to
pharmacy visits –
3)/days on ART] g
Variable
median, 24
913 1. Lower PAM (,80%,
80%-94%, and .95%)
more likely to predict VFd
at time of the VL test (P
, .05)
2. Self-reported adherence
did not predict VFd
San Lio et al
[25] (2008)
Prospective
cohort
NGO, free Mozambique No NNRTI (100) PC (Days pills
prescribed – days
pills returned)/
days between ap-
pointments
12 (varied) 394 PAM ,95% predicted
VFh after 12 months of
follow-up (P , .05)
Toure et al
[20] (2008)
Retrospective
cohort
Public,
private and
NGO
Cote d’Ivoire Yes NNRTI (96),
PI, 3NRTI
MPR Days ART given to
patient/days since
ART start to last
visit, or censor if
last visit was after
censor date
Variable
median, 8
10211 1. PAM ,80% predicted in
creases in the CD4 cell
count of ,50 cells after
6 months (P , .01)
2. PAM ,80% predicted
LTFU (P , .01) but not
death over a period of
16 months
Chi et al [19]
(2009)
Retrospective
cohort
Public Zambia Yes NNRTI (100) MPR 100% - [(days late to
pharmacy visits –
3)g/days on ART]
12 (0–12) 27115 1. PAM ,80% predicted
lower CD4 cell counts
after 18–36 months
(P , .01)
2. decreasing PAM
adherence rates (.95%,
80%-94%, and ,80%)
predicted LTFU after
12-36 months of ARTh
(P , .01) PAM ,80%
predicted death (P , .01)
at 12–36 months but
higher strata (80%-94%
and .95%) did not
Danel et al
[22] (2009)
Clinical trial
(one or both
of VF or IF)
Free Cote d’Ivoire Yes NNRTI (87),
PI
MPR Days ART delivered/
days in the
interval
6 (0–6) 208 PAM of .90% did
not predict CD4 cell
counts of .350 cells/lL
plus VL suppression at
36 months
496
d
C
ID
2011:52
(15
F
eb
ru
ary)
d
H
IV
/A
ID
S
30 (6–36) 208 PAM .90% predicted
either or both of the fol-
lowing: a CD4 cell count
.350 cells/lL and VL
suppression at 36
months (P , .01)
Rougemont
et al [24]
(2009)
Prospective
cohort
Private Cameroon Yes NNRTI (99),
PI
PPU ‘‘Nonadherent was
defined as being
.2 weeks late to
pick-up medica-
tion or as ‘‘aban-
doned ART’’ on
phone tracing
6 (0–6) 194 ’’Nonadherent’’ status
predicted VFd (P , .01);
no different than CD4 cell
count change over 6
months at predicting
VFd; day 30 Self-reported
adherence did not pre-
dict 6-month VFd
Ross-Degnan
et al [21]
(2010)
Retrospective
cohort
Public,
private,
and NGO
Sub-Saharan
Africa
(multiple
countries)
Yes NNRTI, PI
(NR)
MPR Days with ART/days
since ART start
Variable
median, 6
409 1. PAM ,80% (but not
80%-90% or 90%-
100%) predicted lower
CD4 cell counts (at
4-9 months), compared
with PAM 100%
(P , .05)
2. PAMs were not directly
compared with self-re-
ported adherence
MPR ’’Nonadherent’’ was
defined as .30
days without re-
ceipt of ART
Variable
Median, 6
409 ‘‘Nonadherent’’ status
predicted lower CD4 cell
counts at 4-9 months
(P , .05)
NOTE. ART, antiretroviral therapy; ARV, antiretroviral; IF, immunological failure; LTFU, lost to follow-up; MPR, medication possession ratio; NGO, nongovernmental organization; NNRTI, nonnucleoside reverse-
transcriptase inhibitor; NR, not reported; PC, pill count; PI, protease inhibitor; 3NRTI, triple nucleoside reverse-transcriptase inhibitor; 3TC, lamivudine; VF, virological failure; PPU, pill pick-up; VL, viral load.
a Data are ART regimens for that study. Number in parentheses represents percentage of subjects receiving the predominant regimen.
b Duration of adherence assessment, with the months over which assessed in parentheses. If there was a variable duration of adherence assessment, than the median, mean, or range is listed.
c Number after PAM is the percentage adherence.
d Single viral load above threshold.
e Single viral load above threshold after previous VL suppression.
f Because remnant pills were counted to determine adherence, this measure comes under the PC category despite being referred to as medication possession ratio in the study.
g Subjects not late to pharmacy visit until after 3 days, to account for routine provision of 3 days extra ART.
h Statistical significance for association was not reported, so we determined statistical significance using raw data with the v2 test.
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Table 3. Reported Associations with Pharmacy-Based Adherence Measures (PAMs) in High-Income Countries
Study (year) Design Type of care Region
ART naive
(%)
ART regimen
(%)a
PAM
category
PAM descriptionin
study
PAM dura-
tion, monthsb
Sample
size Key findingsc
Maher et al
[42] (1999)
Retrospective
cohort
VA, minor
costs
USA No (26) PI (100) PPU Adherence’ occurred
if the patient con-
sistently filled 4
prescriptions on
time ‘‘non-
adherent did not
do this)
4 (varied) 205 Adherent status
predicted VL suppres-
sion (P, .01) and CD4
cell count increase (P
, .01), whereas ’’non-
adherent’’ status pre-
dicted VL suppression
(P , .05) but not CD4
increase over 5–9
months of follow-up
Singh et al
[46] (1999)
Prospective
cohort
VA, private USA No (7) NR PPU Adherence occurred
if refills picked-up/
refills prescribed
was .90%
6 (varied) 123 Adherence predicted
greater change in the
CD4 cell count (P ,
.05)
Descamps
et al [33]
(2000)
Case-control
study in an
RCT
Free France Yes PI, 2NRTIf PC (Pills prescribed –
remnant pills)/pills
to cover the in-
terval
6 (0–6) 116 Mean PAM for
zidovudine and in-
dinavir predicted VL
rebounde (P , .05)
Low-Beer
et al [41]
(2000)
Retrospective
cohort
Public Canada Yes NNRTI, PI
(NR)
MPR Months ART
prescribed/
months follow-up
in 1st year
12 (0–12) 886 Increasing PAM strata
(,70%,70%-80%,
80%-90%, 90%-
95%, and 95%-
100%) predicted VL
suppression during
follow-up (median
duration of follow-up,
19 months; P , .01)
Liu et al [40]
(2001)
Prospective
cohort
Private USA Yes NNRTI, PI
(NR)
PC 1 – [(actual pills –
expected pills)/
pills per dose/pre-
scribed doses for
the period ]
2 (0–2)
6 (0–6)
108 1. Increasing PAM strata
predicted VL suppres-
sion at 2 and 6months
(P , .01)
2.no difference was
shown between PC
and MEMS at pre-
dicting VL at 2 and 6
months, but both
were superior to self-
reported adherence at
2 months (P , .01)
McNabb et al
[43] (2001)
Prospective
cohort
Private USA No PI (63),
NNRTI,
2NRTI
PC (1) doses taken/
doses prescribed,
OR if return after
30 days, then(2)
doses taken/
doses required for
interval
3 (varied) 40 PAM and self-report
changes were not as-
sociated with VL
change, whereas in-
creasing MEMS adher-
ence was associated
with decreasing VL (P
, .05) and VL sup-
pression (P , .01)
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Hogg et al
[38] (2002)
Retrospective
cohort
Public Canada Yes PI (73),
NNRTI
MPR Months ART
prescribed/
months follow-up
in first year
12 (0–12) 1282 PAM adherence of
,75% predicted
mortality, or mortality
plus new AIDS di-
agnosis, over maxi-
mum follow-up of 50
months (P , .01)
Alcoba et al
[30] (2003)
Retrospective
cohort
NR Spain No PI (100) MPR Patient was ‘‘
nonadherent’’ if
(days in the interval
– days dispensed)/
days in the interval
is .10%
3 (varied) 106 ‘‘Nonadherent’’ status,
self-report, and ARV
plasma levels were
not associatedwith VL
Wood et al
[48] (2003)
Retrospective
cohort
Public Canada Yes NNRTI, PI
(NR)
MPR Months ART
prescribed/
months follow-up
in 1st year
12 (0–12) 1422 PAM adherence of
.95% predicted time
to VL suppression and
time to VL rebounde
over follow-up, which
was NR but variable
and maximum of 67
months (P , .01)
Grossberg
et al [37]
(2004)
Retrospective
cohort
VA, minor
costs
USA No(35) NNRTI, PI,
3NRTI (NR)
MPR (Total pills/
daily number of
pills)/days
between refills
3 (varied) 110 Self-reported
adherence and in-
creasing PAM strata
predicted VL reduc-
tions (P , .01), apart
from self-report in
ART naive
Kitahata et al
[39] (2004)
Retrospective
cohort
Free ART USA Yes PI (78),
NNRTI
MPR Mean for all ARVs of
[(1 – days without
ARV)/days in the
interval]
6 (0–6) 212 1. Increasing PAM strata
(,70%, 70%-90%,
and .90%) predicted
viral reboundh (P ,
.01) and higher CD4
cell counts over 12–24
months (P , .05)
2. PAM adherence
,70% predicted new
AIDS or death, com-
pared with PAM ad-
herence of .70%,
over 24 months (P ,
.01) (but PAM adher-
ence of 70%-90%,
compared with
.90%, did not)
Wood et al
[47] (2004)
Retrospective
cohort
Public Canada Yes PI (69),
NNRTI
MPR Months ART
prescribed/
months follow-up
in 1st year
12 (0–12) 1522 PAM adherence ,75%
predicted a lower in-
crease in the CD4 cell
count over 24 months
(P , .01), whereas
PAM strata .75% in-
creasingly predicted
increases in the CD4
cell count over 24
months (P , .01)
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Fairley et al
[34] (2005)
Retrospective
cohort
Public Australia No NNRTI, PI
(NR)
MPR DaysARTprescribed/
days in the interval
Variable
range, 12-44
752 Increasing PAM and
self-reported adher-
ence predicted VL
suppression (P , .01)
Fletcher et al
[35] (2005)
RCT (Prior VF on
PI regimen)
Free ART USA No NNRTI 1 PI
(100)
PC (doses dispensed –
doses returned)/
doses dispensed
1(0–1) 220 PAM did not predict VL
changes at 4 months;
self-reported adher-
ence (P , .05) (n 5
244) and ARV plasma
levels (P , .05) (n 5
180) predicted VL
changes at 4 months,
wheras MEMS did
not (n 5 62)
Harrigan et al
[10] (2005)
Retrospective
cohort
Public Canada Yes PI (74),
NNRTI
MPR Months ART
prescribed/
months follow-up
in 1st year
12 (0–12) 1191 PAM adherence of
80%-90% is the high-
est predictor of single
and multiple category
HIVDR over 24
months, compared
with PAM adherence
of 0%-20% (P , .01)
King et al [28]
(2005)
RCT Free ART Multi- conti
nent
Yes PI (100) PC Pills consumed/pills
expected to be
consumed
Variable
range, 2 – 3
590 Decreasing PAM strata
increasingly predicted
VFg (P , .01);the
mean PAM adher-
ence rate was lower
in persons with de-
tectable HIVDR to PI
and/or 3TC (P , .01)
Inciardi et al
[29] (2005)
Retrospective
cohort
Private USA No NNRTI (56),
PI
MPR Sum of (interval days
– ARV days) for all
ARVs/sum of interval
days for all ARVsi
Variableh 94 Decreasing PAM
adherence was asso-
ciated with VL in-
crease (P , .01)
Gross et al
[36] (2006)
Retrospective
cohort
Public Canada No NNRTI, PI
(NR)
MPR (Days ART [any
ARV] dispensed
between 3 refills
130)/days
between 3 refills
Variable
range, 2-6
1634 Decreasing PAM strata
(,70%, 70%-95%,
and .95%) in a 2-6
observed interval, pre-
dicted a higher propor-
tion with VFd (P, .01)
Yes NNRTI, PI
(NR)
MPR (Days ART [any
ARV] dispensed
130)/fays
between refills
Variable
median, 29
1634 PAM adherence ,95%
(treated as a time-
varying variable, with
or without a 30-day
grace period) pre-
dicted viral rebounde
over the period of
observation (P , .05)
Braithwaite
et al [27]
(2007)
Retrospective
cohort
VA, minor
costs
USA Yes PI (58),
NNRTI,
3NRTI
MPR Days ART
prescribed/days in
interval
12 (0–12) 6394 Increasing PAM strata
increasingly predicted
VL change, VL sup-
pression, or changes
in the CD4 cell count at
12 months
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Townsend
et al [31]
(2007)
Retrospective
cohort
VA, minor
costs
USA No PI(50),
NNRTI,
NRTI
MPR Days ART
prescribed/days
in the interval
6 (varied) 58 PAM was not
associated with VL;
PAM adherence
,70% was associ-
ated with changes in
the CD4 cell count (P
, .05), but PAM ad-
herence of 70%-
90%, compared with
.90%, was not
Saberi et al
[45] (2008)
Retrospective
cohort
Private USA No NNRTI (100) MPR (Pills dispensed/pills
prescribed per
day)/days be-
tween refills
Variable
range, 3-18
151 PAM adherence .85%
maintained VL sup-
pression in 8 of 10
patients between 2
VL measurements
Lima et al
[11] (2009)
Retrospective
cohort
Public Canada Yes PI (64),
NNRTI
MPR Days ART
prescribed/days
of follow-up
Variable
maximum, 30
903 PAM adherence ,95%
predicted mortality
over follow-up period
(maximum, 55
months) (P , .05)
Nellen et al
[44] (2009)
Retro- and
Prospective
cohort
NR Holland No NNRTI (58),
PI, 3NRTI
PPU ART dispensed/ART
prescribed
6 (varied) 115 PAM adherence ,85%
did not predict VFg
(but did for an ART-
naı¨ve subgroup; P ,
.01) over 24 months;
self-reported adher-
ence and ARV plasma
levels did not predict
VFg over 24 months
Cambiano
et al [32]
(2010)
Retrospective
cohort
Public England No PI(47),
NNRTI,
NRTI
MPR Days with >3 ARV
prescriptions/
study interval
6 (varied) 1632 PAM strata ,95%
predicted (P , .01)
viral rebound, but
PAM adherence of
95%-99% did not, h
over the subsequent
9 months, compared
with PAM adher-
ence of 100%
NOTE. ART, antiretroviral therapy; ARV, antiretroviral; HIVDR, HIV drug resistance; MEMS medication event monitoring system; MPR, Medication possession ratio; NNRTI, nonnucleoside reverse-transcriptase
inhibitor; NR, not reported; PC, pill count; PI, protease inhibitor; PPU, pill pick-up; RCT, randomized control trial; 3NRTI, triple nucleoside reverse-transcriptase inhibitor; 3TC, lamivudine; 2NRTI, double nucleoside reverse-
transcriptase inhibitor; VA, veterans affairs hospital; VF, virological failure; VL, viral load.
a Data are ART regimens for that study. The numbers in parentheses represent the percentages of subjects receiving the predominant regimen.
b Duration of adherence assessment, with the months over which assessed in parentheses. If there was a variable duration of adherence assessment, than the median, mean, or range is listed.
c The number after ’’PAM’’ is the percentage adherence.
d Two viral loads separated in time above threshold.
e Two viral loads above threshold after previous VL suppression.
f All patients received triple-drug PI regimens for 3 months and were then randomized to receive double-NRTI (50%) or 1 PI plus 1 NRTI (36%) or to continue the PI regimen (14%).
g Single viral load above threshold.
h Single viral load above threshold after previous VL suppression.
i ‘‘Interval days’’ was the sum of multiple 3-month periods prior to VL tests performed over a 2-year period, and ‘‘ARV days’’ was the sum of ARVs prescribed over these same periods.
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44] or estimated adherence over shorter durations of assessment
(4 weeks) [35].
Given the importance of PAMs in predicting virological
failure or suppression, we considered 2 important sources of
study heterogeneity: the duration of adherence assessment and
the temporal relationship between the adherence assessment and
viral load testing.
The duration of adherence assessment was most commonly
the first 6 months [17, 22, 24, 31–33, 39, 40, 44] or 12 months
[17, 27, 41, 48] after ART initiation but ranged widely (range, 1–
44 months). All studies with a duration of adherence assessment
greater than 6 months demonstrated association with virological
failure or suppression [4, 17, 22, 23, 25, 27, 34, 36, 41, 48].
However, only 11 (79%) of 14 studies demonstrated an asso-
ciation when the duration of adherence assessment was 2–6
months. Notably, associations were maintained over shorter
durations of assessment (2–6 months) when larger sample sizes
were used (.115 subjects) [17, 18, 24, 26, 28, 32, 36, 42, 46, 49],
suggesting that studies that involved shorter durations of ad-
herence assessment or smaller sample sizes lack power to detect
statistically significant associations.
The time at which viral load was assessed varied and oc-
curred either at the end of the period of adherence assessment
or at a future time point. Fourteen (88%) of 16 studies
demonstrated an association between PAMs and virological
failure or suppression at the end of adherence assessment [4,
17, 18, 22–28, 30, 31, 33, 34, 36, 40], whereas in 5 (63%) of 8
studies, PAMs were predictive of future outcomes (range, 1–
55 months after adherence assessment) [17, 22, 32, 39, 41, 42,
44, 48]. In 2 studies, PAMs were found to be more predictive
of virological outcomes at the end of the period of adherence
assessment than at a future time point. However, the duration
of adherence assessment used to predict the future outcome
was shorter in both studies, making it difficult to draw further
conclusions [17, 22].
Association with Nonvirological Outcomes
All studies that assessed the association between PAMs and CD4
cell count response demonstrated that lower levels of adherence
were associated with a poorer CD4 cell count responses [19–22,
27, 31, 39, 42, 46, 47]. Of the 6 studies documenting association
between PAMs and mortality [11, 13, 19, 20, 38, 39], all but 1
[20] demonstrated increasing mortality with lower levels of
adherence. In addition, 2 large studies that assessed African
treatment programs showed an association between lower in-
dividual adherence and subsequent classification as lost-to-
follow-up during the first 12 months after ART initiation [19] or
after a median of 7.7 months [20]. Importantly, authors of the
study in which PAMs were associated with loss to follow-up and
not with mortality acknowledge that many subjects who were
lost to follow-up were likely to have died [20].
Data regarding the association between poor adherence to
ART, as estimated by PAMs and HIV drug resistance, were
limited. However, 2 studies that involved ART-naive patients
receiving NNRTI- or protease inhibitor (PI)–based regimens
[10, 28] demonstrated an association between adherence and
acquired HIV drug resistance.
Studies Assessing Pharmacy and Nonpharmacy Adherence
Measures
Ten studies documented PAMs and self-reported adherence and
their associations with virological outcomes. Both PAMs and
self-report measures were associated with virological outcomes
in 3 studies; however, the superiority of one measure over the
other could not be inferred [26, 34, 37]. In 4 studies, PAMs
predicted virological outcomes, whereas self-reported adherence
did not [23, 24, 26, 37]. In 1 study that compared PAMs with
self-reported adherence using receiver operating characteristic
curves, the PAM was superior to self-reported adherence (P ,
.001) [40]. In contrast, self-reported adherence was superior to
a PAM in 1 study [35] in which a 4-week PC assessment failed to
predict change in viral load 12 weeks later, whereas improved
self-reported adherence measured at the later time point was
predictive of a viral load reduction. In 3 additional studies,
neither the PAMs nor self-reported adherence predicted viro-
logical outcome [30, 43, 44].
Three studies compared PAMs with use of MEMS caps [35,
40, 43]. Better adherence by both measures predicted virological
suppression in 1 study [40], neither predicted viral load change
in a second study [35], and only use of MEMS cap predicted
viral load change in the third [43].
In 3 studies [30, 35, 44] in which PAMs were not predictive of
virological outcome, antiretroviral plasma levels were also de-
termined and found to be predictive in only one [35].
Studies Assessing Different PAMs
Only 1 study compared different PAMs by investigating 2 dif-
ferent PC measures—one incorporating time into the de-
nominator and the other without. Lower estimates of adherence
by both PC measures predicted virological failure at 6 and 12
months [26]. The ability of the 2 PAMs to predict virological
failure was not directly compared; thus, superiority could not be
established. Interestingly, the PC measure using time in the
denominator classified more individuals as nonadherent and
provided greater variability in adherence estimates.
PAM THRESHOLDS AND RELATIONSHIP TO
TREATMENT OUTCOMES
To identify patients at risk for suboptimal clinical or virological
response using PAMs, an understanding of the relationship
between adherence and outcomes, including potential adher-
ence thresholds or cutoffs, is essential. Studies commonly report
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adherence estimates dichotomously or across >3 strata. All
studies that stratified adherence estimates were reviewed to
identify potential threshold effects.
PAM Thresholds and Virological Outcomes
Historically, .95% patient adherence to ART has been cited as
the threshold to achieve virological suppression. This threshold
was based on a single study of ART-experienced patients re-
ceiving unboosted-PI regimens [7]. Subsequent studies have
suggested that adherence levels of ,95% are associated with
virological suppression in a considerable proportion of patients
receiving NNRTI or boosted-PI regimens [6, 28, 50]. Seven
studies using PAMs with stratified adherence estimates [4, 23,
28, 32, 36, 39, 41] failed to detect a threshold effect. Interestingly,
in 2 studies, when 100% adherence was used as the highest
stratum, no significant difference in the rate of viral rebound was
observed, compared with levels of adherence of 95%–99% [32]
and 90%–99% [4]; however, both studies reported decreased
risk of viral rebound for every 10% increase in adherence across
all strata. The ability of some studies to detect a threshold effect
may have been limited by the fact that patients received different
ART regimens [32, 36, 39, 41]. However, 2 studies that assessed
only NNRTI-based regimens [4, 23] reported virological failure
rates of 29% at 80%–95% adherence [23] and of25% at 80%–
99% adherence [4]. These observations are consistent with
studies using self-reported adherhence, unannounced PCs, and
use of MEMS caps for patients receiving NNRTI regimens in
which the majority of individuals had virological suppression
in adherence strata below 95% [6, 50].
PAM Thresholds and Mortality
Four studies reported adherence across >3 strata and observed
a threshold effect for mortality. For individuals receiving pre-
dominantly NNRTI [13, 19] or unboosted-PI regimens [38, 39],
>2 adherence strata above 70% [39], 75% [38], or 80% [13, 19]
did not differ in their ability to predict mortality, but lower
adherence strata did predict increased mortality. Importantly,
investigators attempted to account for ‘‘reverse causation’’ (ie,
cessation of ART because of reasons related to poor survival) by
using prolonged durations of adherence assessment before ob-
serving subjects for survival outcomes. On the basis of these
data, a threshold effect predicting increased mortality among
patients with a level of adherence of ,80% noted by use of
PAMs may serve as a potential target for adherence inter-
ventions, especially if available resources are limited.
PAM Thresholds and HIV Drug Resistance
Two studies described entirely [28] or predominantly (74% of
subjects) [10] ART-naive populations who had received un-
boosted-PI regimens, with those who had adherence rates of
75%–90% having the highest risk for developing resistance.
Because of these limited findings, we were unable to draw
conclusions about adherence thresholds for the emergence of
HIV drug resistance. Importantly, no studies examined the
relationship between PAMs and drug resistant HIV in patients
exclusively receiving NNRTI or boosted-PI regimens.
USE OF PAMS TO MONITOR ADHERENCE AND
TREATMENT OUTCOMES
PAMs are ideally suited to monitoring adherence because they
are objective and can be easily derived from data routinely
collected for other purposes, such as clinical care, medication
billing, fulfillment of legal requirements, or drug supply man-
agement. Importantly, PAMsmay overestimate actual pill taking
if individuals discard or share pills and, therefore, estimate
maximum possible adherence. In addition, PAMs do not pro-
vide information on patterns of nonadherence known to be
associated with the development of resistance to NNRTIs [51,
52].
Despite their limitations, in settings in which frequent routine
viral load monitoring is not available, PAMs can play an im-
portant role in monitoring individual and population-level ad-
herence to ART. Although prospective studies of adherence
interventions and viral load testing targeted at patients with
lower levels of adherence, as determined by PAMs, have not
been reported, findings from 2 studies are optimistic [17, 36]. In
a study conducted in sub-Saharan Africa, PAMs were superior
to CD4 cell count criteria in predicting virological failure, and
when PAMs were performed before determinations of viral load
and CD4 cell count, PAMs were as accurate as CD4 cell count
changes in predicting virological failure. These results support
the use of PAMs for potential identification of patients at risk of
future virological failure [17]. In a second study, which was from
Canada, analysis of repeated measures of adherence, which ac-
count for changes in adherence over time, predicted future viral
rebound [36], suggesting that routine surveillance of patient
adherence with PAMs can be used to alert clinicians to possible
future virological failure.
Use of PAMs to monitor adherence requires the following
minimum data: ART regimen dispensed, date of dispensing, and
number of days of ART dispensed. Selection of a PAM will
depend on available resources at a site or in a program, as well as
a local assessment of the strengths and limitations of different
PAMs. MPR estimates are themost studied and incorporate time
in the denominator (Table 1); thus, patients need to return to the
dispensary before their medication finishes if taken as prescribed,
to be considered 100% adherent. PC and PPU measures that do
not incorporate time in the denominator (Table 1) may over-
estimate adherence, because patients may use all dispensed ART
but do so over longer periods than intended. PC measures are
limited by the increased resources required to routinely count
and record remnant pills at each clinic or pharmacy visit. In
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addition, if patients do not bring all remnant pills for counting
or share or lose pills, the rate of adherence will be overestimated.
Although PC measures may provide a more accurate assessment
of adherence by accounting for unused ART, to our knowledge,
no data comparing PC to non-PC PAMs are available. PPU
measures are the least studied PAM. Unlike MPR and PC
measures, PPU estimates are dichotomous and, therefore, do not
provide a range of adherence, limiting their ability to identify
individuals in need of increased adherence support.
In the absence of data suggesting an advantage of PC over
non-PC measures, and considering the extra resources required
to count remnant pills, we do not suggest using PC measures.
Furthermore, measures incorporating the number of days for
which ART was prescribed in their definition, such as MPR and
some PPU, measures are likely to be the most informative.
Available data suggest that shorter durations of adherence as-
sessment (<6 months) may be less accurate at predicting viro-
logical outcome. Moreover, PAMs are more likely to accurately
predict outcomes at the end of a period of adherence assessment
than at future time points. Not surprisingly, the balance of
studies suggests that PAMs are superior to self-reported ad-
herence in predicting virological outcome. Finally, a threshold
effect for mortality is observed at adherence levels of 70%–80%,
in contrast to virological outcomes, for which no adherence
thresholds were observed.
PAM-based adherence estimates can be used by pharmacists
and other health care providers to promote ART adherence.
Although the literature on pharmacist-directed interventions is
limited, pharmacy-based adherence interventions have success-
fully combined adherence education [53-55], tailoring regimens
to patient lifestyles [54, 56], and the management of adverse
drug reactions [55, 56], resulting in improved adherence [53, 54,
56] and improved virological [53, 55] and immunological [55]
response. Further investigation of these interventions is war-
ranted in HICs and in LMICs where similar interventions have
not been reported.
FUTURE RESEARCH NEEDS
Although many studies have assessed various PAMs and their
associations with clinical and virological outcomes, significant
gaps in our understanding remain. Research is needed to
compare different PAMs in the same population and against
other adherence measures and biomarkers, such as antiretroviral
levels in hair. In addition, the optimal duration of adherence
assessment remains to be clarified for different clinical and vi-
rological outcomes. Also, because the relationship between ad-
herence and virological outcomes varies over time [57] and by
regimen [6, 50], studies should investigate the predictive value of
PAMs in both ART-naive and ART-experienced patients re-
ceiving different regimens.
The potential benefit of PAMs includes the identification of
individuals at risk for virological failure and undesirable treat-
ment outcomes. Prospective studies incorporating PAMs with
interventions designed to improve adherence, clinical outcome,
and virological outcome have not been reported but are neces-
sary if PAMs are to be used to optimize clinical care. Researchers
attempting to design such studies will face multiple challenges,
such as calculating accurate adherence estimates, devising tools
for clinicians to easily interpret PAM results, and correctly ap-
plying interventions to at-risk patients.
CONCLUSIONS
Pharmacy-based methods for estimating adherence during
routine clinical care are heterogeneous, yet they predict viro-
logical and other clinical outcomes in the majority of studies.
Limited comparative data suggest that PAMs are likely superior
to self-reported adherence measures. Nevertheless, additional
studies are needed to clarify this finding and to identify which
PAM parameters are most predictive of clinical or virological
outcomes and which measure is best suited to each treatment
setting. Available evidence suggests that PAMs aremore accurate
in predicting current rather than future outcomes and that
PAMs applied over shorter durations of adherence assessment
(<6-months) are likely to be less predictive of outcome than
PAMs estimated over longer durations. In conclusion, available
data suggest that MPR and PPU estimates, which include the
number of days for which ART was prescribed, are appropriate
minimum-resource methods to assess patient adherence to
ART.
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